Chronic Disease
Featured Topics
Lead story
Other featured articles
-
Conflicts of Interest in Dialysis: A Barrier to Policy Reforms
What are the possible benefits and risks of nephrologist’s financial participation in dialysis facility joint venture (JV) arrangements and financial participation in End‐stage Kidney Disease Seamless Care Organizations (ESCOs)? Eugene Lin and co-authors examine possible mechanisms for disclosure and reporting of such arrangements as well as risk mitigation.
Posted in -
Four Years Into MACRA: What Has Changed?
Changes to nephrology reimbursement present a unique opportunity to improve patient outcomes in a cost‐effective way. A multidisciplinary effort among policy makers, nephrology providers, and patient advocacy groups is critical to ensure these changes in care delivery safeguard and improve patient health.
Posted in -
Policy Issues in Dialysis Care
The challenges that policymakers face when trying to encourage the delivery of high quality, cost‐efficient dialysis care to all patients who require dialysis are evident in the state of dialysis care today.
Posted in -
Outcome Measures for Oncology Alternative Payment Models: Practical Considerations and Recommendations
Oncology care will benefit from a more rigorous approach to quality assessment. The success of oncology alternative payment models will require a robust set of quality measures that are relevant to patients, providers, and payers.
Posted in
About this section
Chronic diseases are among the most preventable and costliest conditions, consuming the overwhelming majority of Medicare resources. The Schaeffer Center assembles leading minds from across disciplines to address this challenge, striving to simplify labyrinthine systems of care and promote healthier outcomes.
Our Experts On Chronic Disease
Our Work In Chronic Disease
-
Economic Value of Anti–Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States
A new study suggests benefits to patient health and society top billions of dollars, or more, if adherence to wet age-related macular degeneration treatments could be improved.
Categorized in -
Treatments for the Leading Cause of Blindness in the US Generate $0.9 to $3 Billion for Society, According to New Economic Analysis
A new study suggests benefits to patient health and society top billions of dollars, or more, if adherence to wet age-related macular degeneration treatments could be improved.
Categorized in -
The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey
Research by Jakub Hlavka and colleagues suggests a combination of brief cognitive tests and blood-based biomarker tests will allow primary care physicians to identify patients with potential early stage Alzheimer’s disease efficiently and triage them for further evaluation.
Categorized in -
Diabetes Studies Reveal How Insurance and Ethnicity Can Affect Outcomes
USC Schaeffer Center experts found significant racial and ethnic disparities in diabetes complications and examined the impact of the ACA on patients with diabetes in two separate studies.
Categorized in -
Extended-Release Formulation and Medication Adherence
Suboptimal adherence to chronic medications undermines treatment effectiveness and costs the U.S. as much as $289 billion annually. This is the first study to analyze the impact of extended-release formulations on long-term adherence.
Categorized in -
Are We Ready to Treat Alzheimer’s?
Alzheimer’s research has been associated with many more downs than ups, but with Biogen’s surprising decision to file for market authorization of aducanumab, the next major challenge is for national healthcare systems to get ready.
Categorized in